Last reviewed · How we verify
Terlipressin acetate continuous infusion — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Terlipressin acetate continuous infusion (Terlipressin acetate continuous infusion) — BioVie Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Terlipressin acetate continuous infusion TARGET | Terlipressin acetate continuous infusion | BioVie Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Terlipressin acetate continuous infusion CI watch — RSS
- Terlipressin acetate continuous infusion CI watch — Atom
- Terlipressin acetate continuous infusion CI watch — JSON
- Terlipressin acetate continuous infusion alone — RSS
Cite this brief
Drug Landscape (2026). Terlipressin acetate continuous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/terlipressin-acetate-continuous-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab